Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Defends Duragesic, Ortho Evra Patches

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety of transdermal delivery system is not undermined by recent reports of adverse events with the products, the firm says. Mylan defends its own transdermal fetanyl patch, stating that FDA safety review pertains to Duragesic.

You may also be interested in...



Ortho-McNeil Faces $150 Mil. Wrongful Death Suit Over Ortho Evra

Lawsuit alleges 17-year-old woman died from blood clots as a result of wearing the Ortho Evra patch.

Ortho-McNeil Faces $150 Mil. Wrongful Death Suit Over Ortho Evra

Lawsuit alleges 17-year-old woman died from blood clots as a result of wearing the Ortho Evra patch.

Ortho-McNeil Conducting Additional Studies To Assess Ortho Evra Blood Clotting Risks

The firm updated labeling to include a new bolded warning regarding increased hormone exposure with the patch versus oral contraceptives.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel